There is a growing trend in medicine to treat to essentially healthy people. Perhaps the most obvious example is people with cholesterol 'causes'. You could be healthy, fit and active, healthy weight, a non-smoking, eating a healthy diet, but that doesn't necessarily mean that no you purchase on a drug to lower cholesterol.
The threshold for cholesterol in or through considering the possibility that treatment doctors is 5.0 mmol/l (about 190 mg/dl). Here you can read the UK average cholesterol levels are 5.7 mmol/l (220 mg/dl). Cholesterol is an essential constituent organ, is present in the membranes of all cells in the body and is the 'steroids' essential building block hormones such as cortisol, estrogen, and testosterone.As well as vitamin D.Por therefore do this straight - according to many physicians and scientists have a component of essential in normal body levels endanger persons threatening disease, it is something that requires treatment.
Don't forget also that treatment essentially healthy people with Statins do not save lives.
But the desire that some have to medicating people health does not end with the treatment of normal levels of colesterol.Ahora is expanding in the conditions referred to in things like 'pre-diabetes' and 'pre-osteoporosis'. Calls are coming from certain factions community medical for people deemed at risk of developing conditions be treated in an effort to prevent the actual condition. The theory is that you will help treat individuals 'risk risk'.
British Medical Journal in the this week contains an article by Ray Moynihan [1] and Publisher that accompanies it [2] that addresses some of the issues and policies surrounding 'pre-hypertension' (in the high-end normal is not so high as to be classified as raised blood pressure). While many physicians recognize that this is not a condition itself, there are many people who would like to see this 'precondition' most widely recognized and treated.On what basis? since treatment may reduce the risk of developing high blood pressure (hypertension) - a condition that in turn is associated with increased risk of health such as stroke, and kidney problems.
Testing support that comes from this concept, at least in part, as released in 2006 which found candesartan drub antihypertensive taken two years aid to reduce the risk of developing hypertension people. However, as noted by Ray Moynihan, part 7 of 11 authors of this study stated multiple ties with the pharmaceutical companies, and one was actually employed by Astra-Zeneca (which make candesartan). What this study does not tell us, however, is if you deal with pre-hypertension helps really nobody in terms of risk of illness or death.
Drug company ties are relative to the pharmaceutical industry is to very well out of the sale and processing of preconditions.It is estimated that you one in three adults has 'pre-hypertension', amounting to more than 50 million people in the United States itself only.
However, not everyone, as noted by Ray Moynihan, is so enthusiastic about the concept of pre-hypertension and the concept of treating it. In his piece, Moynihan CITES Curt Furberg, Professor of public health in the Wake Forest University in the United States as saying "is a form of markets more and more pharmaceutical companies".In the 1990s, Professor Furberg sat in the Commission responsible for drawing up guidelines for the treatment of hypertension in the United States.His desire was for the members of the Commission to declare their financial interests conflict.When this was not mandatory, resigned Professor Furberg.Las guidelines were published in 2003, and found that 11 of the 12 members of the Committee had multiple ties to the drug industry.
Moynihan finishes his work with the following paragraph:
"Until now the definition of what constitutes a condition, or prerequisite and guidelines for treatment, have been largely to senior members of the medical profession and its companies estimated, often gathered at company-sponsored drug as the forthcoming Conference in Vienna forums."But for people as Professor Furberg, the profession has been too the industria.Él wondered if it may be time for society in general to take more than one function to decide who should be classified as enfermos.Claramente, prevention of the devastating effects of a heart attack, strokes, and hip fractures is in everyone's interest, but if the problem of billions of healthy people with predisease label is the best way to go requires vigorous debate between a much wider group of voices."How to be more independent and widely representative panels that can deliberate well out of the long shadows of drug industry may be an issue worth reflecting."
In his editorial, Fiona Godlee, BMJ editor writes:
"What" so it time for society in general to take a role in deciding who should be classified as more sick"? unless the profession can recover its independence from commercial influence, my answer is Yes."
I think that it is a real shame that the medical profession that has close commercial médica.En industry links the plus side, however, there is no doubt that these unhealthy ties are getting more and more, exposure and welcome Ray Moynihan and BMJ for his part in esto.Hubo time, perhaps not so long ago, where clear conflict of interest, such as those detailed here would be disclosed or not unheard of.
References:
1 Moynihan r. who benefit from the treatment of hypertension? BMJ 2010; 341:c4442
2 Godlee d. we are at risk of being a risk? BMJ 2010; 341:c4766
Print this post
No comments:
Post a Comment